Navigation Links
Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
Date:10/16/2009

se and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Addit
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... N.J. , May 4, 2015  Soligenix, Inc. ... company developing products that address unmet medical needs in ... that it will be presenting preclinical data from three ... Biological Defense Science and Technology Conference on May 12-14, ... Complex at 701 Convention Plaza, St. Louis ...
(Date:5/4/2015)... 4, 2015   Sentrian ™, the Remote Patient ... with the Scripps Translational Science Institute (STSI) ... patients with chronic obstructive pulmonary disease (COPD), a chronic ... the nation,s third leading cause of death. The patients ... System , a wholly owned subsidiary of Anthem.   ...
(Date:5/1/2015)... DIEGO , May 1, 2015 ... company engaged in the development of biosimilar therapeutics ... announced today that its first quarter 2015 financial ... 2015, before the open of market. At 8:30 am ... call to discuss the financial results and provide ...
(Date:5/1/2015)... According to a new ... Consumables), by Type (Monoclonal, Polyclonal), by Technology (Hybridoma), ... - Analysis & Global Forecast to 2019", published ... Production Market for the forecast period of 2014 ... $2.572 Billion by 2019 from $1.425 Billion in ...
Breaking Biology Technology:Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4
... in the sky. It's a bird. It's a plane. It's super ... in a single bound. Indeed, lately the media has been saturated ... result from the mass exodus of Baby Boomers from the workforce. ... that this trend and its impacts on businesses are black and ...
... Wis. - Fueled by the launch of a ... the world market share leader in the compact ultrasound ... issued by Klein Biomedical Consultants . , ,Klein ... Healthcare has captured 43 percent of the compact ultrasound ...
... Wauwatosa, Wis . - In the medical field, the ... is the sheriff that sets and maintains the standards ... and accreditation of healthcare organizations. , ,It recently shortened ... carry just as much weight. , ,One of these ...
Cached Biology Technology:Shades of gray: Business impacts of an aging workforce 2Shades of gray: Business impacts of an aging workforce 3Shades of gray: Business impacts of an aging workforce 4Shades of gray: Business impacts of an aging workforce 5Shades of gray: Business impacts of an aging workforce 6GE Healthcare leads compact ultrasound market 2Portal to e-records boosts care at Children's Hospital 2Portal to e-records boosts care at Children's Hospital 3
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... Active management of the third stage of labour means ... approach, reveals a thesis from the University of Gothenburg, Sweden, ... studies in the West have shown that heavy bleeding following ... thesis, midwife and researcher Elisabeth Jangsten decided to look at ...
... ANN ARBOR, Mich---University of Michigan researchers have determined ... tumors, providing new evidence that the deadliest form of ... cancer stem cell model. In addition, the researchers ... by switching various genes on and off, making the ...
... the massive glaciers of the greater Himalayan region are ... help the region,s communities prepare for the many ways ... to a new report. Programs that integrate health, education, ... address these impacts, the report states. "The extremely high ...
Cached Biology News:Active management of the third stage of labor reduces risk of bleeding 2More evidence that melanoma does not conform to the cancer stem cell model 2More evidence that melanoma does not conform to the cancer stem cell model 3Time to prepare for climate change 2Time to prepare for climate change 3Time to prepare for climate change 4Time to prepare for climate change 5